Abstract YO35
Case summary
Background - Epidermal growth factor receptors have been commonly associated with rash, diarrhoea and nail changes
Case details - A 57 year female, a known case of EGFR positive metastatic Adenocarcinoma of the lung with Pleural, liver and bone involvement, who had been started on Gefitinib 250 mg once daily upfront eight months ago presented with complaints of involuntary movements involving the jaw and neck since the past 15 days. She had to take resort to clenching her teeth tightly in an attempt to control the movements which interfered with mastication and activities of daily living. They were not suppressed during sleep. She also reported bite marks on the lips and tongue along with mucosal ulcerations. The movements did not involve the upper or lower extremity. There was a positive history of reduced oral intake, however she did not report any difficulty upon swallowing. There were no signs of intracranial metastasis. She had also undergone ICD insertion for right sided malignant pleural effusion and had received palliative radiotherapy for vertebral metastasis (L1-L5). CT scan done at the time of presentation was suggestive of a right hilar mass with pleural, hepatic and bone involvement. Response assessment CT (performed after seven months of upfront EGFR Tyrosine kinase inhibitor) was suggestive of significant interval change in the Lung mass with reduction in size and number of liver lesions. MRI performed after development of abnormal movements was not suggestive of any intracranial pathology. The patient had been started on Gabapentin for targeting the neuropathic component of her bone pain, so a diagnosis of Gabapentinoid induced movement disorder was also considered. She was referred to the medical oncologist, where her EGFR Tyrosine kinase inhibitor was discontinued.
Discussion - She reported an improvement in her symptoms after the discontinuation of the Gefitinib (small cell transformation was suspected). A WHO-UMC category of possible/likely causation and score of 3 was obtained on Naranjo’s algorithm (possible Adverse drug reaction). Gabapentinoids were continued on the subsequent visit. This is one of the first reports of a movement disorder due to a EGFR tyrosine kinase inhibitor.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract